6.3.5.3. immediate (adjuvant) post-operative external irradiation rp (cn0 pn0). four prospective rcts assessed role immediate post-operative rt (adjuvant rt [art]) (undetectable psa mostly defined psa < 0.1 ng/ml), demonstrating advantage (endpoint, development bcr) high-risk patients (e.g., pt2 positive surgical margins isup grade group 3–5 pt3/4 with- without positive surgical margins isup grade group 3–5) post-rp (table 6.3.5.1). aro 96-02 trial, 80% pt3/r1/gs 8–10 patients randomised observation developed bcr within ten years . must emphasised psa undetectable inclusion aro 96-02 trial presents major limitation interpreting findings patients detectable psa would considered salvage therapy rather art . table 6.3.5.1: overview four randomised trials adjuvant surgical bed radiation therapy rp* (without adt) studyninclusion criteriarandomisationdefinition bcr psa (ng/ml)median fu (mo)biochemical progression-free survivaloverall survivalswog 8794 2009 431pt3 cn0 ± involved sm60-64 gy vs. observation> 0.415210 yr.: 53% vs. 30%(p < 0.05)10 yr.: 74% vs. 66% median time:15.2 vs.13.3 yr.,p = 0.023eortc 22911 2012 1,005pt3 ± involved sm pn0 pt2 involved sm pn060 gy vs. observation> 0.212710 yr.: 60.6% vs. 41%(p < 0.001)81% vs. 77% n.s.aro 96-02 2014 388pt3 (± involved sm) pn0 psa post-rp undetectable60 gy vs. observation> 0.05 + confirmation11210 yr.: 56% vs. 35%(p = 0.0001)10 yr.: 82% vs. 86% n.s.finnprostate group 2019 250pt2,r1/ pt3a66.6 gy vs. observation(+ srt)> 0.4 (in 2 successive measure-ments)112 vs. 103 (patients alive)10 yr.: 82% vs. 61%p < 0.00110 yr.: 92% vs. 87% n.s. *see section 6.3.5.1 delayed (salvage) post-radical prostatectomy external irradiation.bcr = biochemical recurrence; fu = follow-up; mo = months; n = number patients; n.s. = significant;os = overall survival; psa = prostate-specific antigen; rp = radical prostatectomy; sm = surgical margin;srt = salvage radiotherapy.